atrovent eco 20 mikrog/annos inhalaatiosumute, liuos
boehringer ingelheim international gmbh - ipratropium bromide monohydrate - inhalaatiosumute, liuos - 20 mikrog/annos - ipratropiumbromidi
dophexine 20 mg/g jauhe juomaveteen/maitoon sekoitettavaksi
dopharma research b.v. - bromhexine hydrochloride - jauhe juomaveteen/maitoon sekoitettavaksi - 20 mg/g - bromheksiini
dacatic injektio/infuusiokuiva-aine, liuosta varten
orion corporation - dacarbazinum - injektio/infuusiokuiva-aine, liuosta varten - dakarbatsiini
ventilastin novolizer 100 mikrog/annos inhalaatiojauhe
viatris oy - salbutamol - inhalaatiojauhe - 100 mikrog/annos - salbutamoli
vectormune fp ilt + ae
ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kana - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiset suidaeille - siat (lihotus) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.